2 completed, 1 active not recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow HM15136: new trials by email Literature Review of HM15136 trials Research Report on HM15136
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) HM15136 - Congenital Hyperinsulinism | Phase 2 | Active not recruiting | Hanmi Pharmaceutical Company Limited | 17 | 2022-05-05 | 2026-08-26 |
| Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities HM15136, Placebo - Obese With Comorbidities, Overweight With Comorbidities | Phase 1 | Completed | Hanmi Pharmaceutical Company Limited | 52 | 2019-08-30 | 2025-01-27 |
| A First-in-Human, Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136(Efpegerglucagon) in Healthy Subjects HM15136, Placebo of HM15136 - Pharmacology | Phase 1 | Completed | Hanmi Pharmaceutical Company Limited | 40 | 2018-10-02 | 2025-02-05 |
Congenital Hyperinsulinism (1)
Hanmi Pharmaceutical Company Limited (3)
South Korea (2) · United States (2) · Germany (1) · Israel (1) · United Kingdom (1)